ERBB2 and breast carcinoma: In general, the expression results are consistent with the idea that the three miRs are endowed with pro-oncogenic properties in Her2+ (SKBR3; MDA-MB453), Basal/TN (MDA-MB157; MDA-MB231) and Luminal/ER+ (MCF-7) breast cancer cells.